Neutralizing anti–IL-1 receptor antagonist autoantibodies induce inflammatory and fibrotic mediators in IgG4-related disease
Authors:
- 8 May 2021
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 149 (1) , 358-368
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (2T32AR050942-11, R01AR06367604, T32AI07290, T32AR007258, U19 AI110495, U19AI11049103, UM1 AI1144295)
- Rheumatology Research Foundation
This publication has 32 references indexed in Scilit:
- Mechanisms of fibrosis: therapeutic translation for fibrotic diseaseNature Medicine, 2012
- Macrophage Matrix Metalloproteinase-9 Mediates Epithelial-Mesenchymal Transition in Vitro in Murine Renal Tubular CellsThe American Journal of Pathology, 2010
- Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type IJournal of Experimental Medicine, 2010
- Amylase α-2A AutoantibodiesDiabetes, 2009
- Serum antibodies to carbonic anhydrase IV in patients with autoimmune pancreatitisGut, 2005
- Reduced anti-TNFα autoantibody levels coincide with flare in systemic lupus erythematosusJournal of Autoimmunity, 2004
- Interleukin-13 Induces Tissue Fibrosis by Selectively Stimulating and Activating Transforming Growth Factor β1Journal of Experimental Medicine, 2001
- Cytokines: Principles and prospectsImmunology & Cell Biology, 1998
- A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonistNature, 1997
- Anti-IL-lα autoantibodies in patients with rheumatic diseases and in healthy subjectsClinical and Experimental Immunology, 1991